Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSPrecision oncology offers to transform cancer care with medicines tailored to each patient by targeting specific bioprocesses, genetic mutations, or by precisely enhancing the individual’s immune system. Within this report, the current use of personalized and precision cancer medicines, associated biomarkers, the pipeline of emerging therapies and development trends are discussed, along with the range of challenges facing oncologists and other stakeholders as advances in cancer treatment shifts even further away from the systemic chemotherapies of the past. In the era of COVID-19, the FDA remains committed to expedited review for oncology products and has provided guidance to assist sponsors making clinical trial modifications due to impacts from the pandemic to ensure the safety of trial participants. Notably, as of July 7, 13 novel oncology products were approved by the agency in 2020, compared to five products in the same time frame in 2019.
This year’s oncology report examines market trends for targeted and predictive biomarker therapies. The number of oncology products that require or recommend biomarker testing prior to use has nearly doubled since 2015 in the United States. The report also provides insights into clinical applications of biomarkers in routine care and clinical trials. Specifically, the number of clinical trials incorporating pharmacogenomic analysis to stratify patients for predictive response, safety, or dosing, has more than doubled since 2010 and represents 42% of oncology trials in 2019. Finally, the report provides an analysis of the pipeline for immuno-oncology and tissue-agnostic products that finds over 700 immuno-oncology therapies in development from Phase I to pre-registration in 2019 along with over 20 tissue-agnostic therapies.
U.S. New Active Substances in Oncology by Year of Indication Approval, 2015-2019
Number and Percentage of Oncology Trials by Biomarker and Immune-oncology Segmentation, 2010-2019
Tissue-Agnostic Pipeline by Phase, Tumor Type, and Biomarkerm 2019